Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice
Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice
复制标题
DOI：
10.1016/s8756-3282(00)00395-1
复制
发表时间：
2000-12-01
期刊：
影响因子：
4.1
通讯作者：
Takaoka, K
中科院分区：
文献类型：
--
作者：
Kinoshita, T;Kobayashi, S;Takaoka, K
在正常小鼠中，给予己酮可可碱 (PTX)（一种甲基黄嘌呤衍生物和环 AMP (c-AMP) 磷酸二酯酶 (PDE) 抑制剂）或咯利普兰（一种 4 型 PDE (PDE4) 特异性抑制剂）可显着增加皮质骨和松质骨量。通过骨密度测定和组织形态计量学对接受 PTX 或 Rolipram 处理的小鼠的椎骨和胫骨进行分析，结果表明 PTX 和 Rolipram 均主要通过加速骨形成来增加正常小鼠的骨量。这些发现表明 PTX 和咯利普兰都可以增强生理性骨形成，从而增加正常小鼠的骨量。讨论了这些药物对于治疗骨质疏松症可能有价值的可能性。 (C) 2000 年，Elsevier Science Inc. 保留所有权利。
The administration of either Pentoxifylline (PTX), a methylxanthine derivative and an inhibitor of cyclic AMP (c-AMP) phosphodiesterases (PDEs), or Rolipram, an inhibitor specific to type-4 PDE (PDE4) in normal mice, significantly increased both cortical and cancellous bone mass. Vertebrae and tibiae from mice treated with PTX or Rolipram were analyzed by means of bone densitometry and histomorphometry, The results revealed that both PTX and Rolipram increased bone mass in normal mice mainly through the acceleration of bone formation. These findings suggest that both PTX and Rolipram can enhance physiological bone formation and thereby increase bone mass in normal mice. The possibility that these agents may be of value for the treatment of osteoporosis is discussed. (C) 2000 by Elsevier Science Inc. All rights reserved.